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Abstract
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, has
achieved high clinical response rates in patients with non–small cell lung cancers (NSCLCs). However, over time, most
tumors develop acquired resistance to EGFR-TKIs, which is associated with the secondary EGFR T790M resistance mutation
in about half the cases. Currently there are no effective treatment options for patients with this resistance mutation. Here
we identified two novel HLA-A*0201 (A2)-restricted T cell epitopes containing the mutated methionine residue of the EGFR
T790M mutation, T790M-5 (MQLMPFGCLL) and T790M-7 (LIMQLMPFGCL), as potential targets for EGFR-TKI-resistant
patients. When peripheral blood cells were repeatedly stimulated in vitro with these two peptides and assessed by antigen-
specific IFN-c secretion, T cell lines responsive to T790M-5 and T790M-7 were established in 5 of 6 (83%) and 3 of 6 (50%)
healthy donors, respectively. Additionally, the T790M-5- and T790M-7-specific T cell lines displayed an MHC class I-restricted
reactivity against NSCLC cell lines expressing both HLA-A2 and the T790M mutation. Interestingly, the NSCLC patients with
antigen-specific T cell responses to these epitopes showed a significantly less frequency of EGFR-T790M mutation than
those without them [1 of 7 (14%) vs 9 of 15 (60%); chi-squared test, p = 0.0449], indicating the negative correlation
between the immune responses to the EGFR-T790M-derived epitopes and the presence of EGFR-T790M mutation in NSCLC
patients. This finding could possibly be explained by the hypothesis that immune responses to the mutated neo-antigens
derived from T790M might prevent the emergence of tumor cell variants with the T790M resistance mutation in NSCLC
patients during EGFR-TKI treatment. Together, our results suggest that the identified T cell epitopes might provide a novel
immunotherapeutic approach for prevention and/or treatment of EGFR-TKI resistance with the secondary EGFR T790M
resistance mutation in NSCLC patients.
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Introduction
Lung cancer is one of the most aggressive malignancies, but
recently significant progress has been made in the therapeutic
strategy against this disease [1–4]. In particular, epidermal growth
factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as
gefitinib and erlotinib, have been developed as a novel treatment
option for patients with non–small cell lung cancers (NSCLCs)
that possess somatic mutations in the tyrosine kinase domain of the
epidermal growth factor receptor (EGFR) gene [5–7]. Prospective
clinical trials of EGFR-TKI treatment in NSCLC patients with
activating EGFR mutations, such as delE746-A750 (exon 19) and
L858R (exon 21), have demonstrated high clinical response rates
of approximately 80% [8–10]. Nevertheless, over time (median of
6–12 months), most tumors develop acquired resistance to EGFR-
TKIs. Intense research into these NSCLCs has identified the
secondary T790M mutation, which occurs in around 50% of
patients with acquired resistance to EGFR-TKIs and is reported
to negate the hypersensitivity of activating EGFR mutations [11–
15]. However, there have been no effective treatment options for
NSCLC patients with this secondary T790M resistance mutation.
In recent years, the field of cancer immunology has moved
forward dramatically due to the identification of numerous
tumor-associated antigens [16–18]. Notably, various approaches
for therapeutic cancer immunotherapies have been developed
and clinically examined, including cancer vaccines using
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tumor-associated proteins or peptides. Although the early-phase
clinical trials demonstrated the feasibility and good toxicity profile
of immunotherapeutic approaches, most of the late-phase
randomized trials, with a few exceptions, failed to show beneficial
therapeutic effects in patients compared to existing treatments
[19,20]. Such unexpected results might be attributed, at least in
part, to the type of vaccine antigens employed for cancer
immunotherapies. Currently, most vaccine antigens are derived
from non-mutated self-antigens [21], which cannot be expected to
show high immunogenicity due to the central and/or peripheral
tolerance mechanism. In contrast, tumor-specific neo-antigens
containing mutated amino acid sequences could be immunogenic,
since they might be recognized as foreign by the host immune
system [22,23]. In particular, vaccine antigens derived from
‘‘driver mutations’’ might be an ideal target for immunotherapy,
since they would rarely be lost from tumor cells via escape from
immunological pressure [24]. Although there have been some
reports demonstrating the feasibility of immunotherapies targeting
mutated antigens [25–27], only a limited number of mutated
antigens have so far been identified as potential targets for
immunotherapies [24]. In NSCLCs, several T cell epitopes
derived from mutated antigens were reported [28–32], but there
have been no reports on the tumor-specific neo-antigens derived
from EGFR driver mutations.
In the current study, we identified HLA-A*0201 (A2)-restricted
antigenic T cell epitopes containing the mutated methionine
residue of the EGFR T790M resistance mutation. Given their
strong immunogenicity for human T cells, the identified T cell
epitopes could provide a novel and promising immunotherapeutic
approach for prevention and/or treatment of the secondary
EGFR T790M mutation in NSCLC patients treated with EGFR-
TKIs.
Materials and Methods
Peptides and cell lines
The peptides containing the wild-type (threonine) or mutated
(methionine) residue at the position 790 of EGFR and control
HLA-A2-restricted peptides, influenza M158-66 (Flu-M1,
GILGFVFTL) and HIV-derived epitope (SLYNTVATL), were
provided by Thermo Fisher Scientific GmbH (Bremen, Germany)
at purities of higher than 90%. T2 cells and NSCLC cell lines,
NCI-H1975 (HLA-A22 T790M+) and HCC827 (HLA-A22
T790M2), were obtained from the American Type Culture
Collection (ATCC; Manassas, VA). PC9 (HLA-A2+ T790M2),
PC9/ZD (HLA-A2+ T790M+), 11–18 (HLA-A2+ T790M2), and
YM-21 (HLA-A2+ T790M2) were obtained as described previ-
ously [33–36]. PC9/ZD cells were established as a gefitinib-
resistant clone from PC9 cells [33], and were shown to harbor the
T790M mutation of EGFR [34]. NCI-H1975-A2 cells were
established by stably transfecting HLA-A2-negative NCI-H1975
cells with the plasmid carrying HLA-A*0201 cDNA (pCMV-
HLA-A*0201) (data not shown). These cell lines were maintained
in RPMI 1640 medium (Life Technologies, Rockville, MD)
supplemented with 10% heat inactivated fetal calf serum (FCS)
(MP Biologicals, Solon, OH), 100 mg/ml streptomycin (Life
Technologies), and 100 IU/ml penicillin (Life Technologies).
Expression of HLA-A2 on their cell surface was examined by
flow cytometry with anti-HLA-A2 mAb (BB7.2; BD Biosciences,
San Jose, CA).
Blood samples from NSCLC patients
Blood samples were obtained from 6 healthy donors and 22
NSCLC patients treated with EGFR-TKI, gefitinib or erlotinib,
between March 2012 and February 2013, at Kurume University
Hospital (Kurume, Fukuoka, Japan) or Sendai Kousei Hospital
(Sendai, Miyagi, Japan). This study was approved by the
Institutional Review Board of Kurume University and Sendai
Kousei Hospital, and conforms to the provisions of the Declara-
tion of Helsinki. All of the patients had the EGFR gene mutations
in exon 19 (delE746-A750) or exon 21 (L858R), and had received
or were receiving gefitinib or erlotinib for treatment against
advanced diseases at the blood sampling. For analysis of EGFR
gene mutations in exon 19 (delE746-A750) or exon 21 (L858R),
the peptic nucleic acid-locked nucleic acid (PNA-LNA) polymerase
chain reaction (PCR) clamp method was adopted, using protocols
described previously [37].
The EGFR T790M mutation was examined in cell-free DNA
obtained from plasma of the patients, since no biopsy specimens
for DNA analysis could be obtained because of difficult
accessibility of tumors during or after EGFR-TKI-treatment.
Heparinized whole blood from patients was centrifuged for 10 min
at 400 g. After centrifuging for 10 min at 2000 g again, plasma
was transferred to a new tube and stored at –80uC until use. Cell-
free DNA was isolated from 200 ml of thawed plasma and eluted in
60 ml extraction buffer by using QIAamp DNA Blood Mini kit
(Qiagen, Hilden, Germany). The EGFR T790M mutation was
detected by the droplet digital PCR (ddPCR) system (QX100TM
Droplet DigitalTM PCR system; Bio-Rad Laboratories, Hercules,
CA) according to the manufacturer’s instructions [38]. Briefly, the
PCR reaction mixture was assembled from a 2X ddPCR
Supermix for Probes (Bio-Rad), primers and FAM-labeled probe,
and cell-free DNA (8 ml) in a final volume of 20 ml. The primers
and FAM-labeled probes for T790M mutation (EGFR mutant
allele assay, Hs00000106_mu) and reference (EGFR reference
assay, Hs00000173_rf) were purchased from Applied Biosystems
(Taqman Mutation Detection Reference Assays, Life Technolo-
gies). The droplets were generated from the prepared PCR
reaction mixture and droplet generator oil by using QX100
Droplet Generator (Bio-Rad). Thermal cycling conditions were
95uC X 10 min (1 cycle), 95uC X 30s and 65uC X 60s (40 cycles),
98uC X 10 min (1 cycle), and 4uC hold by C1000 Touch Thermal
Cycler (Bio-Rad). Analysis of the ddPCR data was performed with
QuantaSoft analysis software that accompanies QX100 Droplet
Reader (Bio-Rad). A diluted DNA from NCI-H1975 (T790M+)
and T2 cells (T790M2) was used as a positive and negative control
for this assay, respectively. Samples were prepared in duplicate for
each experiment, and repeated twice to confirm reproducibility.
Clinical responses to EGFR-TKIs were evaluated by computed
tomography (CT) according to the Response Evaluation Criteria
in Solid Tumors (RECIST). Responses were confirmed at least
every 4 weeks (for partial response) or every 6 weeks (for stable
disease). Among the 22 NSCLC patients, 8 patients were sensitive
to EGFR-TKIs at the time of the blood sample collection. In
contrast, 14 patients showed primary (n = 2) or acquired (n = 12)
resistance to EGFR-TKIs at the blood sampling.
Prediction of HLA-A2-binding peptides containing the
mutated methionine residue of the EGFR T790M
mutation
Recent benchmarking has shown that NetMHC 3.2 (http://
www.cbs.dtu.dk/services/NetMHC) and BIMAS (http://www-
bimas.cit.nih.gov/molbio/hla_bind) are among the best preform-
ing systems for predicting HLA-A2 binding peptides [39]. Thus
NetMHC 3.2 and BIMAS were employed to predict 9-mer or 10-
mer HLA-A2 binding peptides from the EGFR-T790M. For
prediction of 11-mer HLA-A2 binding peptides, only NetMHC
3.2 was used because BIMAS does not perform predictions on
T Cell Epitopes Derived from EGFR T790M Mutation
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11-mer peptides. The top ranking peptides by either or both of
these prediction servers were selected for further evaluation.
HLA class I stabilization assay
The actual binding of predicted peptides to HLA-A2 molecules
was evaluated by an MHC class I stabilization assay with TAP-
deficient RMA-S cells stably transfected with the HLA-A*0201
gene (RMA-S/A2), according to the previously reported method
with some modifications [40]. Briefly, RMA-S/A2 cells were
cultured for 18 hours at 26uC in 1 ml of RPMI 1640 medium in
the presence of synthetic peptides (10 mg/ml) and b2-microglo-
bulin (2 mg/ml; Cortex Biochem, San Leandro, CA). After being
washed, the cells were cultured for 3 hours at 37uC, and then
stained with anti-HLA-A2 mAb (BB7.2), followed by flow
cytometry (FACSCanto II; BD Biosciences). Data were analyzed
by using the Diva software package (BD Biosciences). The binding
capability of each peptide to HLA-A2 molecules was evaluated by
the increase in mean fluorescence intensity (MFI) of the HLA-A2
expression, as follows: MFI increase (%) = (MFI with a given
peptide – MFI without peptides)/(MFI without peptides) X 100.
The HLA-A2-restricted influenza M158-66 epitope (Flu-M1) was
used as a positive control.
Generation of antigen-specific T cells
Peptide-specific T cell lines were generated according to the
previously reported method with slight modifications [41]. In brief,
peripheral blood was obtained from 6 HLA-A2+ healthy donors
and 22 HLA-A2+ NSCLC patients after written informed consent.
HLA-A2 positivity was confirmed by flow cytometry with anti-
HLA-A2 mAb (BB7.2). Peripheral blood mononuclear cells
(PBMCs) (16105 cells per well) purified by Ficoll-Paque Plus
(GE Healthcare, Uppsala, Sweden) density centrifugation were
incubated with 10 mg/ml of each peptide in 96 round well plates
(Nunc, Roskilde, Denmark) in 200 ml of the culture medium
containing 45% RPMI 1640, 45% AIM-V medium (Life
Technologies), 10% FCS, IL-2 (20 IU/mL; AbD Serotec,
Kidlington, UK), and 0.1 mM MEM nonessential amino-acid
solution (Life Technologies). At every 3 or 4 days, half of the
culture medium was removed and replaced by new medium
containing the corresponding peptide (10 mg/ml) and IL-2
(20 IU/mL). After 14 days, the cells were used for interferon
(IFN)-c ELSPOT or cytotoxicity assays.
Immune assays
For IFN-c ELISPOT assay (MBL, Nagoya, Japan), the peptide-
stimulated PBMCs (26104 cells/well) were cultured in duplicate
for 18 hours at 37uC with T2 cells (16104 cells/well) loaded with
or without the indicated doses of specific or control peptides in a
96-well ELISPOT plate (MultiScreen HTS; Millipore, Bedford,
MA) coated with anti-human IFN-c mAb. After the plates were
washed, biotin-conjugated anti-human IFN-c mAb, streptavidin-
ALP, and BCIP/NBT substrate were added to develop the spots,
in accordance with the manufacturer’s instructions. The numbers
of spots were then counted by an ELISPOT reader (CTL-
ImmunoSpot S5 Series; Cellular Technology, Ltd., Shaker
Heights, OH). The peptide-stimulated PBMCs were also tested
for their reactivity against tumor cell lines by IFN-c ELISPOT
assay. In some cases, CD8+ T cells were isolated using a CD8
Negative Isolation Kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) from the peptide-stimulated PBMCs. To examine the
HLA class I restriction, 10 mg/ml of anti-HLA class I mAb (W6/
32: mouse IgG2a) was added into wells at the initiation of the
culture. As an isotype control, anti-HLA-DR mAb (L243: mouse
IgG2a) was used.
Peptide-stimulated PBMCs were also tested for cytotoxicity
against tumor cell lines by a standard 6-hour 51Cr-release assay
(PerkinElmer, Waltham, MA) using a MicroBeta2 LumiJET
microplate counter (PerkinElmer). Effector cells and 51Cr-labelled
cells (2000 cells/well) were cultured in duplicate in 96 round well
plates at the indicated effector/target ratios. The spontaneous
release and maximal release were determined by the target cells
cultured in medium without or with 1% Triton X-100 (Wako Pure
Chemical Industries, Osaka, Japan), respectively. The specific lysis
was calculated as follows: specific lysis (%) = [(test release –
spontaneous release)/(maximal release - spontaneous release)] X
100. The means of duplicate samples were used for calculation.
Statistical Analysis
The difference in proportion of the presence of EGFR-T790M
mutation between NSCLC patients with and without EGFR-
T790M-specific immune responses was statistically evaluated by
the chi-squared test (SAS 9.3; SAS Institute Inc., Cary, NC).
Results
Prediction of HLA-A2-binding peptides containing the
mutated methionine residue of the EGFR T790M
mutation
The amino acid sequences (9 to 11-mer) were predicted to bind
HLA-A2 molecule by NetMHC 3.2 and/or BIMAS servers. Eight
peptides (10- or 11-mer) containing the mutated methionine
residue at the position 790 of EGFR (T790M), which showed
better scores by either or both of these prediction servers, were
selected for further evaluation (Table 1). But 9-mer peptides did
not show good scores by the prediction servers.
HLA-A2-binding capability of the EGFR-T790M-derived
peptides
The HLA-A2-binding capability of the selected peptides was
confirmed by cell surface HLA class I stabilization assay with the
TAP-deficient cell line RMA-S, which stably expressed the HLA-
A*0201 gene (RMA-S/A2). As illustrated in Table 1, three of the 8
selected peptides showed substantial binding to HLA-A2. Notably,
the binding affinity of T790M-5 (MQLMPFGCLL) to HLA-A2
was much stronger than that of T790M-7 (LIMQLMPFGCL) or
T790M-8 (IMQLMPFGCLL). The WT-5 peptide containing the
wild-type threonine residue at position 790 of EGFR, which
corresponded to T790M-5, showed high binding capability to
HLA-A2, whereas the WT-7 peptide corresponding to T790M-7
did not bind to HLA-A2.
Immunogenicity of the EGFR-T790M-derived HLA-A2-
binding peptides in T cells from HLA-A2+ normal donors
To examine the immunogenicity of the EGFR-T790M-derived
HLA-A2-binding peptides, PBMCs from 6 different HLA-A2+
healthy donors were repeatedly stimulated with the synthetic
peptides, T790M-5, T790M-7, or T790M-8. As shown in Figure
1, after repeated stimulation, T cell lines secreting IFN-c in
response to T790M-5 and T790M-7 could be established in 5 of 6
(83%) and 3 of 6 (50%) healthy donors, respectively. However,
none of the 6 healthy donors showed antigen-specific T cell
responses to T790M-8.
The T cell lines established after repeated stimulation of
PBMCs with T790M-5 or T790M-7 were then examined for their
reactivity against NSCLC cell lines, including NCI-H1975 (HLA-
A22 T790M+), NCI-H1975-A2 (HLA-A2+ T790M+), and
HCC827 (HLA-A22 T790M2), by IFN-c ELISPOT assay. As
T Cell Epitopes Derived from EGFR T790M Mutation
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shown in Figure 2A, the T cells lines established by T790M-5 or
T790M-7 stimulation showed apparent IFN-c production in
response to NCI-H1975-A2, but not to HLA-A2-negative parental
NCI-H1975. In addition, they showed no responses against an
HLA-A2-negative, EGFR-T790M-negative cell line, HCC827.
The IFN-c secretion from T790M-5- and T790M-7-stimulated T
cells in response to NCI-H1975-A2 was significantly inhibited by
incubation with anti-HLA class I mAb (clone W6/32), but not by
Table 1. HLA-A2-binding capability of the predicted EGFR T790M-derived peptides.
Peptide name Amino acid sequence NetMHC 3.2 ANN IC50 (nM) BIMAS score HLA-binding capability (%)a
T790M-1 VQLIMQLMPF 3705 0.109 0
T790M-2 QLIMQLMPFG 4054 0.943 0
T790M-3 LIMQLMPFGC 837 24.921 0
T790M-4 IMQLMPFGCL 925 6.478 0
T790M-5 MQLMPFGCLL 977 51.770 207.5
T790M-6 LTSTVQLIMQL 4187 NAc 0
T790M-7 LIMQLMPFGCL 530 NA 19.1
T790M-8 IMQLMPFGCLL 118 NA 57.0
WT-5b TQLMPFGCLL 2578 30.453 158.2
WT-7b LITQLMPFGCL 5063 NA 0
Flu-M1 GILGFVFTL 18 550.927 234.4
aHLA-A2-binding capability was estimated by the increase in mean fluorescence intensity (MFI) as determined by flow cytometry after staining of RMA-S/A2 cells with
anti-HLA-A2 mAb, as follows: MFI increase (%) = (MFI with a given peptide – MFI without peptides)/(MFI without peptides) X 100. The experiments were repeated three
times and a representative result is shown.
bWT-5 and WT-7 peptides have wild-type sequences, corresponding to the T790M-5 and T790M-7 peptides, respectively.
cNA, not available.
doi:10.1371/journal.pone.0078389.t001
Figure 1. Immunogenicity of T790M-derived peptides in PBMCs from HLA-A2+ healthy donors. The immunogenicity of T790M-deived
peptides, T790M-5, T790M-7, and T790M-8, was examined with PBMCs from 6 different HLA-A2+ healthy donors. PBMCs were stimulated 5 times with
T790M-5, T790M-7, or T790M-8 peptides (10 mg/ml) every 3 or 4 days. The stimulated PBMCs (26104 cells/well) were examined for reactivity against
T2 cells (16104 cells/well) pulsed with the corresponding peptides or control HIV peptide (10 mg/ml) by IFN-c ELISPOT assay. The assays were carried
out in duplicate wells, and representative wells in each donor are shown. The numbers of spots are shown for each well. Positive antigen-specific T
cell responses are marked by closed boxes.
doi:10.1371/journal.pone.0078389.g001
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an isotype control mAb, anti-HLA-DR (clone L243), confirming
that this response was MHC class I-restricted (Figure 2B).
The reactivity of T cells against NSCLC cell lines was also
investigated by 51Cr-release assay. Both T790M-5- and T790M-7-
stimulated T cells showed higher cytotoxic activity against NCI-
H1975-A2 than HLA-A2-negative NCI-H1975 (Figure 3A).
Moreover, they demonstrated strong cytotoxic activity against
HLA-A2-positive PC9/ZD cells harboring the EGFR T790M
mutation (HLA-A2+ T790M+), but not against the original PC9
(HLA-A2+ T790M2) or HCC827 (HLA-A22 T790M2) without
the T790M mutation (Figure 3B). These results suggested that
both T790M-5 and T790M-7 epitopes might be expressed on the
surface of NSCLC cells harboring the EGFR T790M mutation in
an HLA-A2-restricted manner.
Cross-reactivity of T790M-5-stimulated T cells against the
wild-type epitope or T790M-8
Since T790M-5 was different from the corresponding wild-type
peptide, WT-5, by only a single amino acid sequence, we
examined whether T cell lines established after repeated stimu-
lation with T790M-5 could show reactivity against the corre-
sponding wild-type peptide WT-5 (Figure 4). When the T790M-5-
stimulated T cell lines were stimulated by a higher dose (1 mg/ml)
of peptides for ELISPOT assay, the wild-type peptide WT-5
induced apparent, but weaker antigen-specific T cell responses,
compared to the mutant peptide T790M-5. When a lower dose
(10 ng/ml) of peptides was used for the assay, the T790M-5-
stimulated T cell lines responded only to T790M-5, but not to
WT-5. This finding suggested that the T cells established by
stimulation with the mutant peptide T790M-5 possessed a
substantial, but weaker (around 100 times less) cross-reactivity to
the corresponding wild-type peptide. Similarly, the T cell lines
established by T790M-5 stimulation possessed an apparent, but
weaker (around 100 times less) cross-reactivity to the T790M-8
peptide, which has one additional amino acid extension at the N-
terminal of T790M-5 (Figure 4). We did not examine the cross-
reactivity of T790M-7-stimulated T cell lines, since the corre-
sponding wild-type peptide, WT-7, could not bind to HLA-A2
(Table 1).
Immunogenicity of the wild type HLA-A2-binding
peptides in T cells from HLA-A2+ normal donors
To examine the immunogenicity of the wild type HLA-A2-
binding peptides, PBMCs from 6 different HLA-A2+ healthy
donors were repeatedly stimulated with the synthetic peptides,
WT-5 and WT-7. As shown in Figure 5A, after repeated
stimulation, a T cell line secreting IFN-c in response to WT-5
could be established in 1 of 6 (17%) healthy donors. However,
none of the 6 donors showed antigen-specific T cell responses to
WT-7 (data not shown), because this peptide could not bind to
HLA-A2 (Table 1). When the WT-5-stimulated T cell line was
stimulated by a higher dose (1 mg/ml) of WT-5 peptide for
ELISPOT assay, it showed a strong antigen-specific response. In
contrast, when a lower dose (10 ng/ml) of WT-5 peptide was used
for the assay, the T cell line showed a much weaker response
Figure 2. Reactivity of T790M-5- or T790M-7-stimulated T cells against HLA-A2+ NSCLC cells harboring EGFR T790M mutation. (A)
CD8+ T cells (26104 cells/well) isolated from the T790M-5-stimulated PBMCs by magnetic beads were examined for their reactivity against different
NSCLC cell lines (16104 cells/well), NCI-H1975 (HLA-A22 T790M+), NCI-H1975-A2 (HLA-A2+ T790M+), or HCC827 (HLA-A22 T790M2), by IFN-c ELISPOT
assay (left panel). The T790M-7-stimulated PBMCs (26104 cells/well) were similarly examined for their reactivity against the same tumor cell lines by
IFN-c ELISPOT assay (right panel). The assays were carried out in duplicate wells, and representative wells are shown. The numbers of spots are shown
for each well. The experiments were repeated with blood from three different donors, and representative results are shown. (B) The T790M-5 and
T790M-7-stimulated PBMCs (26104 cells/well) were examined for their reactivity against NCI-H1975-A2 cells (16104 cells/well) by IFN-c ELISPOT assay
in the absence or presence of 10 mg/ml of anti-HLA class I (W6/32) or anti-HLA-DR (L243) mAb. The assays were carried out in duplicate wells, and the
means of spot numbers from duplicate wells are shown. The experiments were repeated with blood from three different donors, and a representative
result is shown.
doi:10.1371/journal.pone.0078389.g002
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(Figure 5A), suggesting that the avidity of T cell receptor (TCR) of
WT-5-stimulated T cells might be low.
The WT-5-stimulated T cell line was then examined for their
reactivity against NSCLC cell lines, including NCI-H1975 (HLA-
A22 T790M+), NCI-H1975-A2 (HLA-A2+ T790M+), HCC827
(HLA-A22 T790M2), PC9 (HLA-A2+ T790M2), PC9/ZD (HLA-
A2+ T790M+), 11–18 (HLA-A2+ T790M2), and YM-21 (HLA-
A2+ T790M2), by IFN-c ELISPOT assay. As shown in Figure 5B,
the WT-5-specific T cells showed reactivity against none of HLA-
A22 cell lines (HCC827 and NCI-H1975), HLA-A2+ T790M+ cell
lines (NCI-H1975-A2 and PC9/ZD), or HLA-A2+ T790M2 cell
lines (PC9, 11–18, and YM-21).
Immunogenicity of T790M-5 and T790M-7 epitopes in T
cells from HLA-A2+ NSCLC patients
We further investigated the immunogenicity of the T790M-5
and T790M-7 epitopes in 22 HLA-A2+ NSCLC patients
harboring the EGFR gene mutations in exon 19 (delE746-A750)
or exon 21 (L858R), who had been sensitive (n = 8) or resistant (n
= 14) to the EGFR-TKI treatment at the blood sampling (Table
2). Among the 8 patients who had been sensitive to EGFR-TKIs, 4
patients (50%) showed antigen-specific T cell responses to T790M-
5 or T790M-7. In contrast, only 3 of 14 EGFR-TKI-resistant
patients (21%) revealed positive T cell responses to these epitopes.
Interestingly, the NSCLC patients with antigen-specific T cell
responses to these epitopes showed a significantly less frequency of
EGFR-T790M mutation than those without them [1 of 7 (14%)
vs 9 of 15 (60%); chi-squared test, p = 0.0449], indicating the
negative correlation between the immune responses to the
EGFR-T790M-derived epitopes and presence of EGFR-T790M
mutation in NSCLC patients. Of note, the T790M-5 and T790M-
7-specific T cell lines established in these NSCLC patients were
functional, since they showed substantial cytokine production or
cytotoxicity against the NSCLC cell lines that harbored both the
EGFR-T790M mutation and HLA-A2 (data not shown).
Discussion
The clinical benefit of EGFR-TKIs has been demonstrated in
NSCLC patients with activating EGFR mutations [8–10], but
most tumors develop acquired resistance via several different
mechanisms, including the secondary T790M mutation that
occurs in around 50% of patients with EGFR-TKI resistance
[11–15]. However, there have been no effective treatment options
for NSCLC patients with the secondary T790M resistance
mutation. In the current study, we identified two HLA-A2-
restricted cytotoxic T cell (CTL) epitopes containing the mutated
methionine residue of the EGFR T790M mutation, T790M-5 and
T790M-7. Given their high immunogenicity in human T cells,
these epitopes might provide a novel immunotherapeutic ap-
proach for NSCLC patients with the T790M mutation. The
limitation of the current study is that the T cell epitopes that we
identified can be applicable only to NSCLC patients with HLA-
A*0201. Although to increase the population coverage, we
examined the immunogenicity of T cell epitopes restricted to
other prevalent HLA-A types, including HLA-A*2402 and HLA-
A*1101, we have not identified immunogenic epitopes restricted to
these HLA-A types (data not shown). Nevertheless, HLA-A*0201
is one of the most prevalent HLA-A types in the world (http://
Figure 3. Cytotoxicity of the T790M-5- or T790M-7-stimulated T cells against NSCLC cells harboring EGFR T790M mutation. (A) The
T790M-5- or T790M-7-stimulated PBMCs were examined for their cytotoxicity against the NSCLC cell lines (26103 cells/well), NCI-H1975 (HLA-A22
T790M+) or NCI-H1975-A2 (HLA-A2+ T790M+), at the indicated effector/target ratios. (B) The T790M-5- or T790M-7-stimulated PBMCs (16104 cells/well)
were examined for their cytotoxicity against the NSCLC cell lines (26103 cells/well), PC9 (HLA-A2+ T790M2), PC9/ZD (HLA-A2+ T790M+) or HCC827
(HLA-A22 T790M2), at an effector/target ratio of 5:1. The assays were carried out in duplicate, and the means of duplicate samples were used for
calculation. The experiments were repeated with blood from three different donors, and a representative result is shown.
doi:10.1371/journal.pone.0078389.g003
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www.pypop.org/popdata/2008/byfreq-A.php), and many of
the peptides binding to HLA-A*0201 with high affinity have
been shown to crossreact with other HLA-A2 supertype molecules,
including HLA-A*0202, HLA-A*0203, HLA-A*0204, HLA-
A*0205, HLA-A*0206, HLA-A*0207, HLA-A*6802, and
HLA-A*6901 [42]. It would be of interest to determine whether
the T790M-5 and T790M-7 epitopes can crossreact with other
HLA-A2 supertype molecules.
For inducing effective anti-tumor immune responses, tumor
antigens should be sufficiently immunogenic to stimulate
Figure 4. Cross-reactivity of T790M-5-stimulated T cells against the wild-type or T790M-8 peptide. The T790M-5 stimulated PBMCs
(26104 cells/well) were examined for reactivity against T2 cells (16104 cells/well) pulsed with T790M-5, WT-5, or T790M-8 at the indicated
concentrations by IFN-c ELISPOT assay. The assays were carried out in duplicate wells. Representative wells (A) and the means of spot numbers from
duplicate wells (B) are shown. The experiments were repeated with blood from two different donors, and a representative result is shown.
doi:10.1371/journal.pone.0078389.g004
Figure 5. Reactivity of WT-5-stimulated T cells from an HLA-A2+ healthy donor. (A) PBMCs from an HLA-A2+ healthy donor were stimulated
5 times with WT-5 peptide (10 mg/ml) every 3 or 4 days. The WT-5-stimulated PBMCs (26104 cells/well) were examined for reactivity against T2 cells
(16104 cells/well) pulsed with WT-5 or control HIV peptide at the indicated concentrations by IFN-c ELISPOT assay. The assays were carried out in
duplicate wells, and representative wells are shown. The numbers of spots are shown for each well. (B) The WT-5-stimulated PBMCs (26104 cells/well)
were examined for their reactivity against different NSCLC cell lines (16104 cells/well), including NCI-H1975 (HLA-A22 T790M+), NCI-H1975-A2 (HLA-
A2+ T790M+), HCC827 (HLA-A22 T790M2), PC9 (HLA-A2+ T790M2), PC9/ZD (HLA-A2+ T790M+), 11–18 (HLA-A2+ T790M2), and YM-21 (HLA-A2+
T790M2), by IFN-c ELISPOT assay. The assays were carried out in duplicate wells, and representative wells with the spot numbers are shown. The data
were from a single donor, since WT-5 was not immunogenic in 5 other healthy donors tested.
doi:10.1371/journal.pone.0078389.g005
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antigen-specific T cells with high avidity. However, the T cell
repertoires available for non-mutated ‘‘self-antigens’’ might have
relatively low TCR avidity to them, since T cell reactivity against
them can occur only when T cell tolerance is incomplete. In
contrast, the ‘‘neo-antigens’’ derived from mutated amino acid
sequences could be tumor-specific, and T cell repertoires with high
TCR avidity to them might be available due to the lack of central
and/or peripheral T cell tolerance [23,24]. Indeed, in the current
study, 5 of 6 healthy donors (83%) showed T cell responses to the
mutated epitope T790M-5, whereas only 1 of 6 (17%) donors
responded to the corresponding wild type epitope WT-5,
suggesting that the immunogenicity of the wild type epitope may
be low. Since WT-5-specific T cells with higher TCR avidity may
be deleted by central and/or peripheral tolerance, only those with
low TCR avidity could be activated. In fact, the WT-5-stimulated
T cells could not react to HLA-A2+ NSCLC cells harboring wild-
type EGFR. It may be possible that the TCR avidity of WT-5-
stimulated T cells was too low to respond to the copy number of
naturally processed WT-5 epitopes arrayed on HLA-A2+ NSCLC
cells harboring wild-type EGFR.
In T790M-5 and T790M-7, the threonine residue at the 1st and
3rd positions of wild type epitopes is replaced by the mutated
methionine residue, respectively. Although the amino acid residues
at the 2nd and C-terminal positions of epitopes have been known
to act as the main anchoring sites in HLA-A*0201 [42], those at
the 1st or 3rd positions of epitopes have also been reported to
substantially affect the binding capability of peptides to HLA-
A*0201 [43–47], which might modulate the immunogenicity [48].
Indeed, as shown in Table 1, the cell surface HLA class I
stabilization assay demonstrated that T790M-5 and T790M-7
showed higher binding capability to HLA-A*0201 than the
corresponding wild-type peptides, WT-5 and WT-7, respectively.
In addition, side chains of amino acid residues at the 1st position of
some epitopes have been suggested to directly contact with TCRs
and affect the interaction between the peptides and TCRs [49].
Therefore, the higher immunogenicity of T790M-5 and T790M-7
epitopes could possibly be explained by these mechanisms.
Recent analyses on T cell reactivity in cancer patients showed
that a significant fraction of T cells recognized mutated neo-
antigens, but not non-mutated self-antigens, in human cancers
[22,24]. In addition, T cell responses against mutated neo-antigens
are expected not to show autoimmune toxicity against normal
healthy tissues, suggesting that they might be a highly attractive
target for immunotherapeutic manipulation. A large series of
immunotherapy trials using non-mutated self-antigens demon-
strated that clinical response rates were disappointingly low
(around 3–5%) [19], but some studies have shown the potential
benefit of targeting mutated neo-antigens [25–27]. For example,
Sampson et al. demonstrated that peptide vaccines targeting
EGFR variant III (EGFRvIII), which is a constitutively activated
and immunogenic mutation not expressed in normal tissues but
widely expressed in glioblastoma multiforme (GBM), were capable
of inducing potent T- and B-cell immunity in GBM patients, and
successfully eliminated tumor cells which expressed the targeted
antigen, leading to an unexpectedly long survival time without any
evidence of symptomatic collateral toxicity [25]. Weden et al.
showed that a vaccine composed of synthetic long mutant K-RAS
peptides induced long-term immune responses together with a
potential clinical benefit in patients with pancreatic cancer after
surgical resection [26]. Considering these feasible results of
targeting mutated neo-antigens, cancer vaccines using the CTL
epitopes derived from the T790M mutation, T790M-5 and
T790M-7, might be promising for the treatment of NSCLC
patients with this mutation. In particular, since the T790M
mutation seems to be critical for acquired resistance to EGFR-
TKIs [11–15], the selection of antigen loss variants as immune
escape might be avoided during immunotherapy and tumor
evolution.
Interestingly, the current study showed that the NSCLC
patients with antigen-specific T cell responses to EGFR-T790M-
derived epitopes showed a significantly less frequency of EGFR-
T790M mutation than those without them, indicating the negative
correlation between the immune responses to the EGFR-T790M-
derived epitopes and presence of EGFR-T790M mutation in
NSCLC patients. This finding could possibly be explained by the
hypothesis that immune responses to the mutated neo-antigens
derived from T790M might prevent the emergence of tumor cell
variants with the T790M resistance mutation in NSCLC patients
during EGFR-TKI treatment. Alternatively, it may be possible
that the presence/occurrence of EGFR-T790M inhibits immune
responses to the EGFR-T790M-derived epitopes. To further
clarify the causal relationship between immune responses to the
T790M-derived neo-antigens and the presence/occurrence of
EGFR-T790M in NSCLC patients, both antigen-specific immune
responses and T790M mutation status remain to be monitored at
different time points (before, during, and after EGFR-TKI
treatment) in the same patients in future study.
In the current study, T cells stimulated with T790M-5 showed
cross-reactivity against the corresponding wild-type WT-5 peptide.
However, it should be noted that the avidity of TCR to the WT-5
peptide in the T790M-5-stimulated T cells seemed to be around
100-times less than that to the T790M-5 peptide. Indeed, the
T790M-5-stimulated T cells reacted to the PC9/ZD cells
harboring the EGFR-T790M mutation, but not to the original
PC9 cells expressing EGFR without this mutation. Based on this
finding, the cross-reactivity of the T790M-5-stimulated T cells
might not be high enough to induce autoimmune toxicity against
normal tissues expressing wild-type EGFR.
In summary, we identified two novel HLA-A2-restricted,
T790M-derived epitopes, which were highly immunogenic for
human T cells. Our findings suggested that recognition of T790M-
derived neo-antigens can occur in healthy donors and cancer
patients, even in the absence of immunotherapy. Although more
studies would be required to investigate whether immune
responses to the identified epitopes are associated with clinical
benefits and can be selectively enhanced by immunotherapies, the
current study could provide important information on individu-
alized immunotherapy for NSCLC patients.
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